Medicenna Therapeutics Corp. business relationships
Companies named in Medicenna Therapeutics Corp.’s 20-F filed 2023-06-27, and public companies whose annual reports name Medicenna Therapeutics Corp.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 72 / 100 Top 1% in its category
- Agent readiness
- 0 / 100
- AI adoption
- 8 / 100
Named in Medicenna Therapeutics Corp.’s annual report 2
“DNAtrix's DNX-2401, an oncolytic immunotherapy, has completed enrolment in a Phase 2 clinical trial in collaboration with Merck which evaluated the efficacy and safety of DNX-2401 in combination with pembrolizumab (Keytruda®), Merck's anti-PD-1 therapy.” SEC filing
“On September 13, 2022, we entered into a Clinical Trial Collaboration and Supply Agreement ("CTCSA") with Merck (known as MSD outside the United States and Canada) to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 (programmed death receptor-1) therapy, in the ongoing Pha...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.